Pomalidomide-CH2CONH-C2-COOH

Background Introduction

Pomalidomide-CH2CONH-C2-COOH is a versatile bifunctional molecule designed as an E3 ligase ligand-linker conjugate. This compound features pomalidomide, a well-characterized cereblon (CRBN) ligand, tethered to a carboxylic acid handle via a tailored linker. As an essential building block for next-generation PROTAC (Proteolysis Targeting Chimera) drug development, it plays a pivotal role in targeted protein degradation strategies.

Mechanism

The mechanism of action for Pomalidomide-CH2CONH-C2-COOH centers on its capacity to recruit the CRBN E3 ubiquitin ligase complex. When incorporated into PROTAC molecules, the pomalidomide moiety selectively binds to CRBN, while the carboxylic acid terminus can be conjugated to a ligand targeting the protein of interest. This dual-binding enables the formation of a ternary complex, bringing the E3 ligase into close proximity with the target protein. Consequently, the target protein is ubiquitinated and subsequently degraded by the proteasome, resulting in highly selective protein knockdown.

Applications

Pomalidomide-CH2CONH-C2-COOH is widely used in the design and synthesis of PROTAC molecules and molecular glues for chemical biology and drug discovery. Its applications range from functional protein degradation studies to the development of novel therapies for cancer, neurodegenerative diseases, and autoimmune disorders. Researchers harness this conjugate to enable rapid screening and optimization of PROTACs with enhanced pharmacological profiles. Additionally, the modular structure of this product allows for flexible customization, serving as a foundational tool for academic and pharmaceutical research into targeted protein degradation.

• Carboxylic acid terminus enables versatile conjugation with diverse warheads and linkers in PROTAC design
• Pomalidomide-derived CRBN ligand ensures high-affinity E3 ubiquitin ligase engagement for superior targeted protein degradation